Non-Alzheimer’s Disease Degenerative Dementias: Identifying Prodromal Genetic/familial Phenotypes, Modifying Factors, And Protein Variations Involved In Progression
Funder
National Health and Medical Research Council
Funding Amount
$6,449,246.00
Summary
This proposal will generate new knowledge necessary for advancing the diagnosis of the non-Alzheimer’s disease dementias. We will identify the preclinical forms of frontotemporal dementia and Lewy body dementia using similar methods to those successfully employed to advance diagnosis of Alzheimer’s disease. Importantly, our team has the capacity to translate these protocols into clinical practice and into further advances in biological knowledge that is necessary for future therapeutic targeting
Identifying Neuroimaging Based Biomarkers For Predicting Clinical Progression Along The Lewy Body Disease Spectrum
Funder
National Health and Medical Research Council
Funding Amount
$128,224.00
Summary
Lewy body dementias (LBD) comprise similar but heterogenous group of poorly understood disabling neurodegenerative conditions. This project aims to apply advanced neuroimaging techniques and novel psychological testing to patients at risk of Lewy body disorders as well individuals with established disease to identify novel biomarkers that may explain symptoms of these disorders as well as help predict development of LBD at its early stages when it may be amenable to neuroprotective treatments.
Melanotransferrin: A “Missing Link” And A Novel Pharmacological Target For Treatment
Funder
National Health and Medical Research Council
Funding Amount
$613,848.00
Summary
Despite >30 years of research, the precise function of the protein, melanotransferrin (MTf), is unknown. However, we have breakthrough evidence that MTf stimulates WNT signalling as a major driver in cancer progression. We will investigate this hypothesis, which will underpin new cancer therapies. Indeed, we designed a new class of drugs that target the WNT pathway via up-regulating the WNT inhibitor, NDRG1. This drug (DpC) inhibits MTf expression to block tumour cell growth and metastasis.
Transient Tissue ‘priming’ Via FAK Inhibition To Impair Pancreatic Cancer Progression And Improve Sensitivity To Gemcitabine/Abraxane
Funder
National Health and Medical Research Council
Funding Amount
$643,848.00
Summary
The success of cancer drugs is dependent on many factors including the properties of the tumour tissue. As a tumour grows it changes the tissue around it, and this affects response to treatment. Combining classical biology with engineering to generate 3D models that mimic tumours, along with cutting-edge imaging technology and mouse models, we will target FAK-controlled cancer cell pathways that sense tissue changes, together with already approved cancer drugs to improve patient outcome.
Feeding Behaviour And Obesity Development: Identification Of Novel Intervention Points
Funder
National Health and Medical Research Council
Funding Amount
$923,668.00
Summary
Appetite and food intake is regulated by specific neuronal structures in the brain. The most important area is the hypothalamus from which many neuronal pathways originate to control specific aspects of feeding behaviour and energy usage in the brain and the rest of the body. To better understand the contribution individual neuronal populations make to drive excess food intake we propose a new approach to identify this, making new treatment options for eating disorders and obesity possible.
Therapeutic Targeting Of Cell Cycle Checkpoint Aberrations In Pancreatic Cancer: Personalised Medicine In Action
Funder
National Health and Medical Research Council
Funding Amount
$634,354.00
Summary
Less than 5% of people with pancreatic cancer (PC) survive 5 years, and the odds of patients beating this disease have remained unchanged for 50 years. Consequently, there is an urgent need to develop novel treatment approaches for this highly aggressive cancer. Our study aims to define novel therapeutic strategies for PC utilising specific anti-proliferative therapies and a personalised “companion biomarker” directed strategy.
Achieving Targeted Delivery Of Drugs To Uterine Muscle In Women For The Prevention Of Preterm Labour
Funder
National Health and Medical Research Council
Funding Amount
$469,008.00
Summary
We have patented liposomes targeted to the uterus, which enable us to deliver drugs specifically to the muscle cells of the uterus, increasing safety. The liposomes can be loaded with drugs that either block or promote contractions, creating a versatile drug delivery system that could treat premature labour or postpartum haemorrhage which are major clinical problems. We seek support to demonstrate their effectiveness in mouse and primate models of preterm labour prior to human studies.
Industry Laureate Fellowships - Grant ID: IL230100154
Funder
Australian Research Council
Funding Amount
$2,582,419.00
Summary
Fixing the NDIS: cost, effectiveness and access for psychosocial disability. This project aims to address serious deficits in the operation of the National Disability Insurance Scheme for one of its largest participant groups: people with psychosocial disability. This project expects to develop new data on scheme outcomes, cost-effectiveness and participant experiences to develop an appropriate and implementable program logic to improve supports for this group. Expected outcomes will be scheme r ....Fixing the NDIS: cost, effectiveness and access for psychosocial disability. This project aims to address serious deficits in the operation of the National Disability Insurance Scheme for one of its largest participant groups: people with psychosocial disability. This project expects to develop new data on scheme outcomes, cost-effectiveness and participant experiences to develop an appropriate and implementable program logic to improve supports for this group. Expected outcomes will be scheme reform by implementing a new framework of supports for psychosocial disability and data to improve the operation of national policy for this group more broadly. This should provide significant benefits for the cost-effective operation of the National Disability Insurance Scheme and build research capacity in disability policy.Read moreRead less
Outcomes of specialist disability housing for people with disability. This project aims to systematically investigate the experience, outcomes and economic impact of people with disability moving into specialist disability accommodation housing. Health, wellbeing, community participation, support outcomes and lived experience of people with disability will be measured before moving and over 2 years after they move. The project provides the opportunity to identify the personal, disability, housi ....Outcomes of specialist disability housing for people with disability. This project aims to systematically investigate the experience, outcomes and economic impact of people with disability moving into specialist disability accommodation housing. Health, wellbeing, community participation, support outcomes and lived experience of people with disability will be measured before moving and over 2 years after they move. The project provides the opportunity to identify the personal, disability, housing and support factors that shape outcomes for people with disability. The intended outcome is comprehensive knowledge that can inform policy, build evidence across housing, technology, support and disability sectors and ultimately benefit people with disability by generating innovative practice in housing and support.Read moreRead less
Impact Of An Ivermectin Mass Drug Administration Program Against Endemic Scabies And Strongyloidiasis
Funder
National Health and Medical Research Council
Funding Amount
$1,289,786.00
Summary
Overseas studies suggest sustainable and long term benefits can be obtained through the use of ivermectin in mass drug administration programs to control parasitic infections. Our study will be a critical first step in establishing if such a program can be successful in a remote Indigenous community setting, where the disease burden from scabies and strongyloidiasis (threadworm infections) is very high.